300676 CNE100003449

Report

End-of-day quote Shenzhen Stock Exchange - 2022-08-14
61.16	CNY		-1.62%

07/29	BGI Genomics Forms Medical Testing JV With Tibbiyah in Saudi Arabia	MT
07/27	EXCLUSIVE : EU antitrust regulators likely to block Illumina, Grail deal - sources	RE
07/27	Illumina offers patent licences to rivals, patent truce with BGI - sources	RE

Company

Business Summary

BGI Genomics Co. is a leading provider of genomic and proteomic sequencing services primarily to academic institutions, pharmaceutical companies and healthcare providers. The company also provides genomic solutions for biomarker research and development, screening for some of the trisomies present at birth (trisomy 21, trisomy 18 and trisomy 13) and solutions for neo-antigen identification for immuno-oncology research.

Number of employees : 4 333 people.

Sales per Business

	2020		2021		Delta
Integrated Solutions for Precision Medical Testing	5 562.29	66.2%	3 382.12	50%	-39.2%
Reproductive Health Basic Research and Clinical Application	1 177.90	14%	1 192.49	17.6%	+1.24%
Infection Prevention and Control Basic Research and Clinical Application	669.57	8%	1 158.41	17.1%	+73.01%
Multi-omics Big Data Service and Synthetic	625.92	7.5%	641.59	9.5%	+2.5%
Tumor Prevention and Control and Translational Medicine	351.24	4.2%	379.78	5.6%	+8.12%
Other	10.31	0.1%	11.75	0.2%	+13.96%
CNY in Million

Sales per region

	2020		2021		Delta
China (Excluding Hong Kong, Macau and Taiwan)	2 798.39	33.3%	2 884.58	42.6%	+3.08%
Asia (Including Hong Kong, Macau and Taiwan) and Oceania	3 776.60	45%	2 510.67	37.1%	-33.52%
Europe and Africa	989.70	11.8%	938.75	13.9%	-5.15%
Americas	832.55	9.9%	432.13	6.4%	-48.1%
CNY in Million

Managers

Name	Title	Age	Since
Ye Yin	General Manager & Director	42	-
Qian Xu	Secretary	37	-
Du Yutao, Dr.	Executive Vice President	-	-

Members of the board

Name	Title	Age	Since
Jian Hua Wang	Chairman	67	-
Song Gang Li	Chairman-Supervisory Board	74	-
Ai Min Xu, Dr.	Independent Director	54	-
Yu Hui Wu, Dr.	Independent Director	43	-
Jun Wang	Director	45	-
Ye Yin	General Manager & Director	42	-
Hong Tao Wang	Director	47	-
Ying Jun Sun	Director	50	-
Peng Hui Chen	Director	49	-
Wen Qi Li	Member-Supervisory Board	35	-

Equities

	Vote	Quantity	Free-Float		Company-owned shares		Total Float
Stock A	1	419,914,466	216,195,351	51.5%	6,000,141	1.4%	51.5%

Shareholders

Name	Equities	%
Jian Hua Wang	153,590,467	58.7%
Jun Wang	34,470,455	13.2%
Wanjia Asset Management Co., Ltd.	15,708,531	6.00%
Shenzhen Heyu Gaolin Equity Investment LP	14,791,666	5.65%
Tianjin Liren Enterprise Management Consulting Co. Ltd.	4,037,106	1.54%
BGI Genomics Co. Ltd. ESOP	4,000,000	1.53%
E Fund Management Co., Ltd.	3,314,087	1.27%
Hwabao WP Fund Management Co., Ltd.	3,276,793	1.25%
Qian Xing He	2,820,936	1.08%
BGI Genomics Co., Ltd.	2,711,024	1.04%

Holdings

Name	Equities	%	Valuation
BGI GENOMICS CO., LTD. (300676)	2,711,024	1.04%	24,956,603 USD
LIAONING HE EYE HOSPITAL GROUP CO., LTD.	1,065,173	1.15%	5,756,536 USD

Markets and indexes

- ChiNext

- SZSE 100 /

Stock Exchange Codes


- Bloomberg Code :
- Reuters Code :	300676.SZ
- Datastream Code :

Company contact information

BGI Genomics Co., Ltd.
Building NO.7, BGI Park 21 Hongan 3rd Street
CN-GD 518083 Shenzhen, Guangdong

Phone : +86 755 36307065
Fax :
web site : https://www.bgi.com

Brand Portfolio

In partnership with

Allbrands.markets

More brands of BGI Genomics Co., Ltd.

Analysis

Exclusive: EU antitrust regulators likely to block Illumina, Grail deal - sources

BGI GENOMICS CO., LTD.